At the pulse of heart disease
We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.
Mode of Action
The video illustrates how CDR132L operates in cardiac cells to reverse adverse cardiac remodeling and restore normal cellular functions.
CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study in heart failure patients after myocardial infarction.
News
The transaction on the acquisition of Cardior Pharmaceuticals by Novo Nordisk A/S received all regulatory approvals and is officially completed. As of May 2, 2024, Cardior Pharmaceuticals is a fully owned subsidiary of Novo Nordisk A/S. The transition process is now in progress. Novo Nordisk plans to initiate a second phase 2 trial to investigate Cardior’s lead compound in a chronic heart failure population and advance it further towards market approval.
Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
